GE HealthCare has announced a Distribution and Services Agreement (DSA) with CardioNavix, part of CDL Nuclear Technologies, to expand nationwide access to Flyrcado™ (flurpiridaz F18) injection, its novel cardiac PET imaging agent. The agreement will make Flyrcado available across hospitals, outpatient centers, and private cardiology practices, supporting broader adoption of cardiac PET imaging for the evaluation of known or suspected coronary artery disease (CAD).
Each year, about six million myocardial perfusion imaging (MPI) procedures are performed in the U.S., with PET MPI representing only 5–10% but steadily growing in use. The collaboration is expected to accelerate Flyrcado’s adoption, following results from the international Phase III AURORA trial, which demonstrated higher diagnostic efficacy compared to SPECT MPI in detecting CAD.
“This collaboration with CardioNavix is an important step in making Flyrcado available for patients nationwide, across all sites of care,” said Eric Ruedinger, Vice President and General Manager of GE HealthCare’s Pharmaceutical Diagnostics division for the U.S. and Canada. “CDL Nuclear Technologies is a trusted name in private cardiology and nuclear imaging, and today’s announcement underscores the confidence both organizations have in Flyrcado’s potential. This agreement helps establish the foundation needed to support GE HealthCare’s vision for Flyrcado’s growth in outpatient cardiac PET imaging and reinforces our commitment to innovation and patient-centered care.”
“We’re proud that CardioNavix will be the first distributor to bring Flyrcado to private practice cardiology,” said Lon Wilson, CEO of CDL Nuclear Technologies. “Through our nearly 225 customer sites, CDL and CardioNavix support around 220,000 patient procedures each year with end-to-end cardiac PET solutions—and that number continues to grow. Together with GE HealthCare, we’re helping more providers bring advanced cardiac PET to patients in both private office-based settings and hospitals.”
The rollout of Flyrcado will begin in late 2025 with broader expansion planned through 2026, aligning with GE HealthCare’s strategy to strengthen outpatient imaging capabilities.
GE HealthCare’s Pharmaceutical Diagnostics division, a global leader in imaging agents, supports nearly 130 million procedures annually—equivalent to four patient procedures every second—across cardiology, neurology, and oncology.